Earlier, the Supreme Court ruled that MedImmune could sue Genentech for patent infringement even though MedImmune continued to pay licensing fees to Genentech to use disputed technology to develop the drug Synagis®. At the same time, the U.S. Patent and Trademark Office decided to have a second review of the patents at issue, U.S. Pat. […]